References
- Howell S, Yin PT, Robinson JC. Quantifying the economic burden of drug utilization management on payers, manufacturers, physicians, and patients: study examines the economic burden of drug utilization management on payers, manufacturers, physicians, and patients. Health Aff. 2021;40(8):1206–1214.
- Xcenda . Skyrocketing growth in PBM formulary exclusions raises concerns about patient access. AmerisourceBergen Xcenda; 2020. Available from: https://www.xcenda.com/insights/skyrocketing-growth-in-pbm-formulary-exclusions-raises-concerns-about-patient-access
- Bristol-Myers Squibb and Pfizer. Eliquis (apixaban) [package insert]. U.S. Food and Drug Administration website. [revised 2021 January; cited 2022 May 20]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2021/202155s034lbl.pdf.
- Heidenreich PA, Estes NAM, Fonarow GC, et al. 2020 Update to the 2016 ACC/AHA clinical performance and quality measures for adults with atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2021;77(3):326–341.
- Diagnostic and Interventional Cardiology. New atrial fibrillation guidelines recommend NOACs over warfarin. Wainscot Media; 2019. Available from: https://www.dicardiology.com/article/new-atrial-fibrillation-guidelines-recommend-noacs-over-warfarin#:∼:text=January%2030%2C%202019%20%E2%80%94%20Updated%20atrial,reducing%20the%20risk%20of2520stroke
- Dawwas GK, Cuker A, Connors JM, et al. Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: a population‐based analysis in response to CVS 2022 formulary changes. Am J Hematol. 2022;97(5):E173–E176.
- Waldron B. Nonmedical switching of anticoagulants: the patient impact when formulary exclusions limit drug choice. Res Pract Thromb Haemost. 2022;6(2):e12675.
- Becker Z. CVS re-adds BMS, Pfizer’s Eliquis to formulary after tough negotiations, patient pushback. Fierce Pharma. 2022. Available from: https://www.fiercepharma.com/pharma/eliquis-will-return-cvs-formulary-after-wave-criticism-cites-lower-net-cost-negotiations-bms
- Tepper N. CVS Caremark returns Eliquis to formulary after outcry. Modern Healthcare; 2022. Available from: https://www.modernhealthcare.com/patient-care/cvs-caremark-returns-eliquis-formulary-after-outcry#:∼:text=CVS%20Health%20will%20return%20blood, company%20notified%20providers%20last%20week
- Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944.
- Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
- Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.
- Graham DJ, Baro E, Zhang R, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604.e11.
- Ray WA, Chung CP, Stein CM, et al. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021;326(23):2395–2404.
- Fralick M, Colacci M, Schneeweiss S, et al. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice. Ann Intern Med. 2020;172(7):463.
- Lip GYH, Keshishian AV, Kang AL, et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med. 2021;289(1):42–52.
- Deitelzweig S, Keshishian A, Li X, et al. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. J Am Geriatr Soc. 2019;67(8):1662–1671.
- Lip GYH, Keshishian AV, Kang AL, et al. Effectiveness and safety of oral anticoagulants in patients with nonvalvular atrial fibrillation and diabetes mellitus. Mayo Clin Proc. 2020;95(5):929–943.
- Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study. J Clin Med. 2020;9(6):1633–1657.
- Lip GYH, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):405–414.
- Deitelzweig S, Keshishian A, Kang A, et al. Use of non-vitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and multimorbidity. Adv Ther. 2021;38(6):3166–3184.
- Lip GYH, Keshishian AV, Zhang Y, et al. Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding. JAMA Netw Open. 2021;4(8):e2120064.
- Deitelzweig S, Keshishian AV, Zhang Y, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer. JACC CardioOncol. 2021;3(3):411–424.
- Lip GYH, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases. J Thromb Thrombolysis. 2022;54(1):33–46.
- Clemens A, Noack H, Brueckmann M, et al. Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria. PLoS One. 2014;9(6):e99276.
- Aryal MR, Gosain R, Donato A, et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv. 2019;3(15):2381–2387.
- Dawwas GK, Leonard CE, Lewis JD, et al. Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. Ann Intern Med. 2022;175(1):20–28.
- Streiff MB, Abutalib SA, Farge D, et al. Update on guidelines for the management of cancer-associated thrombosis. Oncologist. 2021;26(1):e24–e40.
- Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–719.
- Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–728.
- Letter from the Partnership to Advance Cardiovascular Health to Troyen Brennan, Chief Medical Officer of CVS Health. 2021 [cited 2022 May 1]. Available from: https://www.stoptheclot.org/wp-content/uploads/2021/12/CVSSwitchLetterFinal.pdf
- American College of Cardiology. ACC, ASH meet with CVS Caremark on new DOAC formulary change. 2022. Available from: https://www.acc.org/latest-in-cardiology/articles/2022/01/13/14/15/acc-ash-meet-with-cvs-caremark-on-new-doac-formulary-change
- Letter from the American Society of Hematology to CVS Health. 2021 [cited 2022 May 1]. Available from: https://www.hematology.org/-/media/hematology/files/advocacy/testimony-and-correspondence/2021/ash-letter-to-cvs.pdf.
- Mehta D, Davis M, Epstein AJ, et al. Impact of formulary restrictions on antiepileptic drug dispensation outcomes. Neurol Ther. 2020;9(2):505–519.
- Zeng F, Chen C-I, Mastey V, et al. Utilization management for smoking cessation pharmacotherapy: varenicline rejected claims analysis. Am J Manag Care. 2010;16(9):667–674.
- Dhamane AD, Baker CL, Rajpura J, et al. Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients. Curr Med Res Opin. 2019;35(10):1769–1776.
- Rivera-Caravaca, JM, Roldán V, Asunción Esteve-Pastor M, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017;117(7):1448–1454.
- Carnicelli AP, Al-Khatib SM, Xavier D, et al. Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. Heart. 2021;107(9):713–720.
- Formulary exclusions, non-medical switching jeopardize disease control, patient trust. Healio Rheumatology. 2020. Available from: https://www.healio.com/news/rheumatology/20201214/formulary-exclusions-nonmedical-switching-jeopardize-disease-control-patient-trust
- Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–1046.
- Bell EJ, Lutsey PL, Basu S, et al. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med. 2016;129(3):339 e19–339 e26.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases. 1987;40(5):373–383.
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of clinical epidemiology. 1992;45(6):613–619.
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical care. 2005;43(11):1130–1139.